Earnings Call Transcripts
Access detailed transcripts and key takeaways from company earnings calls
All Earnings Calls
Lemonade Q3 2025 Earnings Call - Accelerating Growth and Margin Expansion Propelling Profitability Path
Lemonade posted a brisk Q3 2025 with in force premiums hitting $1.16 billion, reflecting an eighth consecutive quarter of accelerating growth and a 42% year-over-year revenue rise. Their key driver wa...
- Lemonade achieved 30% year-over-year growth in in force premiums to $1.16 billion in Q3 2025, marking eight straight quarters of accelerating growth.
- Revenue rose 42% year-over-year to $195 million, outpacing premium growth by 12 percentage points due to strategic quota share reinsurance adjustments.
- Gross profit more than doubled to $80 million with gross margin climbing above 40%, leading the path to EBITDA profitability targeted for Q4 2026.
- +7 more takeaways
ATS Corporation Q2 2026 Earnings Call - Strong Backlog and Margin Expansion Amid Leadership Transition
ATS Corporation reported solid Q2 fiscal 2026 results with order bookings at $734 million, up 6% sequentially, and revenues climbing 19% year-over-year to $729 million, driven by organic growth and su...
- Order bookings reached $734 million, a 6% sequential increase, reflecting solid market performance.
- Q2 revenues rose 19% year-over-year to $729 million, driven mainly by organic growth and acquisitions.
- Adjusted earnings from operations grew 40% year-over-year to $79.1 million, with gross margin improving by 36 basis points.
- +9 more takeaways
Anika 3Q 2025 Earnings Call - Commercial Channel Growth Offsets OEM Pain from J&J Pricing Pressure
Anika's third quarter 2025 results show a classic bifurcation: a 6% total revenue decline driven by ongoing pricing stabilization efforts from OEM partner Johnson & Johnson against a backdrop of robus...
- Total revenue declined 6% year-over-year to $27.8 million, reflecting expected pricing pressure from Johnson & Johnson in the OEM channel.
- Commercial channel revenue surged 22% driven by Integrity's 25% growth in regenerative solutions and strong international OA pain management sales.
- Integrity implant system usage grew for the sixth straight quarter with nearly 300 surgeons performing 500 procedures, with plans to double cases in 2025.
- +17 more takeaways
EyePoint Pharmaceuticals Q3 2025 Earnings Call - Duraview on Track for Mid-2026 Data with Strong Clinical and Financial Momentum
EyePoint Pharmaceuticals reported solid Q3 2025 results, underscoring near-term milestones for Duraview, their lead program targeting wet AMD and diabetic macular edema (DME). The company completed en...
- Duraview program is on track for top-line phase three wet AMD data in mid-2026 from Lugano and Lucia trials, completing rapid enrollment of over 900 patients.
- Duraview is the only sustained-release tyrosine kinase inhibitor (TKI) in development for diabetic macular edema, with phase three DME trials COMO and COPRI set to start dosing in Q1 2026.
- Recent preclinical data shows virolanib, Duraview's active drug, inhibits both VEGF-mediated vascular permeability and IL-6-mediated inflammation, a dual mechanism relevant for multifactorial retinal diseases.
- +7 more takeaways
InTEST Corporation Q3 2025 Earnings Call - Order Growth Led by Automotive and Defense Aerospace Despite Revenue Misses from Technical Delays
InTEST Corporation reported Q3 2025 orders at $37.6 million, the strongest since Q2 2022, driven by robust demand in the automotive EV and defense aerospace sectors, reflecting the success of its mark...
- InTEST's Q3 2025 orders surged to $37.6 million, up $11.4 million sequentially, marking the strongest quarter since Q2 2022.
- Automotive EV led order growth, doubling to $14.6 million, driven by tier one electronics suppliers prepping for 2027 model year programs.
- Defense aerospace orders more than doubled sequentially to $6.4 million, fueled by demand for next-gen weapons systems.
- +7 more takeaways
Diebold Nixdorf Q3 2025 Earnings Call - Strong Retail Recovery and Confident Share Repurchase Boost Outlook
Diebold Nixdorf's Q3 2025 results show steady revenue growth across banking and retail, underpinned by a 25% jump in product orders and a robust $920 million backlog. The company is riding a retail re...
- Q3 revenue grew 2% year-over-year and 3% sequentially, driven by retail acceleration and stable banking.
- Product orders surged 25% year-over-year, with backlog at approximately $920 million.
- Retail segment showed notable momentum: 8% revenue growth and 40% order entry increase year-over-year.
- +13 more takeaways
Sonos Q4 2025 Earnings Call - Embracing a Cohesive Home Sound System to Drive Growth and Profitability
Sonos closed fiscal 2025 with 13% revenue growth in Q4 and strong adjusted EBITDA despite a transitional year marked by strategic overhaul and tariff headwinds. CEO Tom Conrad emphasized a return to t...
- Sonos Q4 2025 revenue grew 13% year-over-year, closing a transitional fiscal year on a strong note with positive adjusted EBITDA.
- Fiscal 2025 was a year of transformation, focusing on restoring software quality, operational discipline, and leadership rebuilding.
- New Chief Marketing Officer Colleen DeCourcy is expected to bring fresh creativity and business growth expertise to Sonos.
- +12 more takeaways
Seres Therapeutics Q3 2025 Earnings Call - Advancing SER-155 with Key FDA Alignment and Capital Focus
Seres Therapeutics reported a net income of $8.2 million in Q3 2025, driven primarily by a $27.2 million gain on the sale of VAST. The company is focused on advancing SER-155, its lead oral live bioth...
- Seres reported $8.2 million net income in Q3 2025 compared to a $51 million loss a year ago, largely due to a $27.2 million gain from VAST sale installment payment.
- SER-155, the lead investigational oral live biotherapeutic aimed at preventing bloodstream infections in alloHSCT patients, showed a 77% relative risk reduction in bacterial bloodstream infections in phase one B study.
- FDA provided constructive feedback on SER-155’s phase two protocol, aligning on study size, dosing, primary endpoint, and interim analysis plan, with no gating items to start pending funding.
- +7 more takeaways
Orion S.A. Q3 2025 Earnings Call - Navigating Demand Slumps and Structural Cost Cuts Amid Market Malaise
Orion S.A. delivered a Q3 2025 report revealing earnings below expectations, challenged primarily by soft demand in key Western markets and elevated tire imports. Despite higher volumes skewed toward ...
- Orion’s Q3 adjusted EBITDA was about $58 million, below expectations but slightly better than mid-October projections.
- Tire production in key markets is down sharply: about 29% in the U.S. and 20-35% across Europe, pressuring carbon black demand.
- Despite solid tire sell-through, elevated tire imports and surplus inventories are reducing OEM production and hitting premium market demand.
- +12 more takeaways
Gladstone Investment Corporation 2Q 2026 Earnings Call - Solid Portfolio Growth Amidst Competitive M&A Landscape and Navigating Uncertainty
Gladstone Investment reported a strong second quarter of fiscal 2026 with adjusted net investment income (NII) of $0.24 per share, covering monthly distributions and supporting a $1.1 billion portfoli...
- Gladstone Investment's adjusted net investment income was $0.24 per share in 2Q fiscal 2026, sufficient to cover monthly shareholder distributions of $0.08 per share.
- Total assets grew by $90 million quarter-over-quarter to $1.1 billion, driven by one new buyout investment and portfolio appreciation.
- The company invested approximately $130 million in three new portfolio companies in the first half of fiscal 2026, nearing the pace of $221 million invested in full fiscal 2025.
- +13 more takeaways